Vemurafenib and ipilimumab: New agents for metastatic melanoma

American Journal of Health-System Pharmacy

Volumn 70, Issue 14, 2013, Pages 1205-1210

  Banaszynski, Megan ^a   Kolesar, Jill M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; COLITIS; DIARRHEA; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ELIMINATION HALF-LIFE; FATIGUE; HUMAN; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PLASMA CONCENTRATION-TIME CURVE; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CANCER; SKIN DISEASE; STEADY STATE; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; MELANOMA; METABOLISM; SECONDARY; SKIN NEOPLASMS; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INDOLES; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84888805558     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120260     Document Type: Review

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29.
2. Buller DB, Cokkinides V, Hall HI et al. Prevalence of sunburn, sun protection, and indoor tanning behaviors among Americans: review from national surveys and case studies of 3 states. J Am Acad Dermatol. 2011; 65(suppl 1):S114-23.
3. National Cancer Institute. Surveillance, Epidemiology and End Results Program. http://seer.cancer.gov/statfacts/html/melan.html (accessed 2012 Jul 2).
4. American Cancer Society. Melanoma skin cancer. www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/melanoma-skin-cancer-key-statistics (accessed 2012 Jul 2).
5. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008; 13:16-25.
6. National Cancer Comprehensive Network. CCN guidelines: melanoma v3.2012. www.nccn.org/professionals/physician-gls/f-guidelines.asp#melanoma (accessed 2012 May 5).
7. Yang AS, Chapman PB. The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am. 2009; 23:583-97.
8. Ravnan MC, Matalka MS. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012; 34:1474-86.
9. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17:2105-16.
10. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353:2135-47.
11. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-54.
12. Ascierto PA, Kirkwood JM, Grob JJ et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012; 10:85.
13. Zelboraf (vemura fenib) package insert. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (accessed 2012 Jul 1).
14. Yervoy (ipilimumab) package insert. www.accessdata.fdagov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (accessed 2012 Jul 1).
15. Karasarides M, Chiloeches A, Hayward R et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004; 23:6292-8.
16. Thomas NE. BRAF somatic mutation in malignant melanoma and melanocytic naevi. Melanoma Res. 2006; 16:97-103.
17. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366:707-14.
18. Chapman PB, Axel H, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364:2507-16.
19. Yang H, Higgins B, Kolinsky K et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical models. Cancer Res. 2010; 70:5518-27.
20. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011; 8:426-33.
21. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363:809-19.
22. Food and Drug Administration. Cobas 4800 BRAF V600 Mutation Test. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm268836.htm (accessed 2012 Jul 3).
23. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-23.
24. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517-26.
25. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010; 11:155-64.
26. Small EJ, Tchekmedylan NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007; 13:1810-5.
27. Hersh EM, Weber JS, Powderly JD et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine. J Clin Oncol. 2008; 26:488s. Abstract.
28. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009; 24:321-5.
29. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005; 23:741-50.
30. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 2009; 15:7471-8.
31. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468:973-7.
32. Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010; 70:5213-9.
33. Thomson Reuters Red book online 2011. www.redbook.com/redbook/online (accessed 2012 May 1).